# Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

> **NCT02178592** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 113 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** DTG 50 mg
- **DRUG:** EFV 600 mg

## Key facts

- **NCT ID:** NCT02178592
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01-23
- **Primary completion:** 2017-11-02
- **Final completion:** 2020-03-06
- **Target enrollment:** 113 (ACTUAL)
- **Last updated:** 2021-01-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178592, "Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02178592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*